Background:
Sarcoidosis is a systemic granulomatous disease of unknown etiology that primarily affects the lungs. One commonly used therapy is methotrexate, an immunomodulating drug, acting through adenosine-mediated mechanisms. This led us to gauge the impact of caffeine, an antagonist of adenosine receptors, on the evolution of sarcoidosis.
Methods:
In a retrospective cohort study involving 46 patients diagnosed with sarcoidosis and followed up at the University Hospital of Coimbra, we ranked the evolution of sarcoidosis based on lung function (evaluated as the forced vital capacity) and computed tomography scan staging and applied a questionnaire to evaluate their estimated caffeine consumption over the past 20 years.
Results:
We found that the consumption of caffeine failed to modify the evolution of the disease, and this was not hindered either by smoking or drug therapy. Further, there was no difference in caffeine consumption between healthy individual and the patient before diagnosis of the disease.
Conclusion:
Overall, these preliminary findings suggest that caffeine consumption fails to affect the initiation or evolution of sarcoidosis, a conclusion that casts doubts on the interest of considering adenosine-based immunomodulatory strategies to manage sarcoidosis.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
0.00 MB0.03 MB 
